Ibrutinib/Rituximab Combo Induced Superior PFS in Older Patients with CLL

The combination of ibrutinib and rituximab demonstrated superior progression-free survival in older patients with previously untreated chronic lymphocytic leukemia.

Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Wayne Kuznar Source Type: news